Editorial

De Pree C , Mermillod B , Hoffmayer P , Beris P . Recombinant human erythropoietin as adjuvant treatment for autologous blood donation in elective surgery with large blood needs (5 units): a randomized study. Transfusion 1997; 37:708–14.

Blumberg N , Heal JM . Transfusion and the immune system: a paradigm shift in progress? Transfusion 1995; 35:879–83.

National Heart, Lung and Blood Institute, expert panel on the use of autologous blood. Transfusion Alert: Use of autologous blood. Transfusion 1995; 35:703–11.

Valbonesi M , Giannini G , Bruni R , Morelli F , Flono G . Cost containment in blood transfusion: clinical and technical aspects. European Soc. of regional anaesthesia: Proceedings of the 5^th Italian chapter meeting “Regional Anaesthesia and acute postoperative pain: clinical aspect and costs. Pugnochiuso June 4/7/1997; 180–2.

Yaw PB , Sentany M , Link WJ , Wahle WM , Glover JL . Tumor cells carried through autotransfusion: Contraindication to intraoperative blood recovery? JAMA 1975; 231:490–1.

Williamson KR , Taswell HF . Intraoperative blood salvage. In: Taswell HF , Pineda AA , eds. Autologous transfusion and hemotherapy. Oxford, Blackwell 1991, pp 122–54.

Miller GV , Ramsden CW , Primrose JN . Autologous transfusion with banked blood during surgery for cancer. Br J Surg. 1991; 78:713–5.

Torre GC , Ferrari M , Favre A , Razzetta F , Borgonovo G . A new technique for intraoperative blood recovery in the cancer patient. Eur J Surg Oncol 1994; 20:565–70.

Perseghin P , Viganò M , Rocco G , Delia Pona C , . Effectiveness of leukocyte filters in reducing tumor cell contamination after intraoperative blood salvage in lung cancer patients. Vox Sang 1997; 72:221–4.

Vamvakas EC , Moore SB . Blood transfusion and postoperative septic complications. Transfusion 1994; 34:714–27.

Dzick S , Blajchman MA , Blumberg N , Kirkley SA , Heal JM , Wood K . Current research on the immunomodulatory effect of allogeneic blood transfusion. Vox Sang 1996; 70:187–94.

Vignali A , Braga M , Gianotti L , . A single unit of transfused Allogeneic blood increases postoperative infections. Vox Sang 1996; 71:170–5.

Hansen E , Wolf N , Knuechel R , Ruschoff J , Hofstaedter FJ , Taeger K . Tumor cells in blood shed from the surgical field. Arch Surg 1995; 130:387–93.

Hansen E , Frey I , Knuechel R , Ruschoff J , Taeger K . Tumor cells in intraoperatively salvaged blood and their elimination by leukocyte filters or gamma irradiation. Anesthesiology 1993; 79(suppl3a):122.

Piantadosi S , Moores DW , McNeally MF . The adverse effect of perioperative blood transfusion in lung cancer. Chest 1994; 106 (suppl 6): 382–4.

Azuma C , Koyama M , Inagaki M , . The influence of perioperative blood transfusion during radical hysterectomy on the prognosis of uterine cervical cancer. Transfusion Sc 1997; 18:55–62.

Wang S , Aldridge L , Collier T , Babcock J , Sniecinski I . Utilization of autologous blood in surgical oncology patients. Transfusion 1997; 37 (suppl): 39.

Neisbach V , Glaser W , Glaser A , Zummerman R , Zingsess JR . Preoperative autologous blood donation in patients with prostatic cancer. Transfusion 1997; 37 (suppl): 38.

Patrone F , Balestrero A , Furando F . Four step high-dose sequential chemiotherapy with double hematopoietic progenitor cell rescue for metastatic breast cancer. J of Clin Oncol 1995; 13:840–6.

Bacigalupo A , Mordini N , Pitto A , . Transplantation of HLA mismatched CD34+ selected cells in patients with advanced malignancies: severe immunodeficency and related complications. Brit J Haematol 1997; 98:760–6.

Kurokawa K. Calcium-regulating hormones and the kidney. Kidney Int 1987; 32: 760–71.

Bricker N.S. , Slatopolsky E. , Reiss E. , Avioli L.V. Calcium, phosphate, and bone in renal disease and transplantation. Arch Int Med 1969; 123: 543–53.

Slatopolsky E. , Calgar S. , Pennel J.P. On the pathogenesis of hyperparathyroidism in chronic renal insufficiency in the dog. J Clin Invest 1971; 50: 492–9.

Portale A.A. , Halloran B.P. , Morris R.C. Physiologic regulation of the serum concentration of 1,25-dihydroxyvitamin D by phosphorus in normal men. J Clin Invest 1989; 83: 1494–9.

Portale A.A. , Booth B.E. , Halloran B.P. , Morris R.C. Effect of dietary phosphorus on circulating concentrations of 1.25-dihydroxyvitamin D and immunoreactive parathyroid hormone in children with moderate renal insufficiency. J Clin Invest 1984; 73: 1580–9.

Tessitore N. , Venturi A. , Adami S. Relationship between serum vitamin D metabolites and dietary intake of phosphate in patients with early renal failure. Min Electrolyte Metab 1987; 13: 38–44.

Lopez-Hilker S. , Dusso A.S. , Rapp N.S. , Martin K.J. , Slatopolsky E. Phosphorus restriction reverses hyperparathyroidism in uremia independent of changes in calcium and calcitriol. Am J Physiol 1990; 259: F432–7.

Kilav R. , Silver J. , Naveh-Many T. Parathyroid hormone gene expression in hypophosphatemic rats. J Clin Invest 1995; 96: 327–33.

Hernandez A. , Conception M.T. , Rodriguez M. , Salido E. , Torres A. High phosphorus diet increase preproPTH mRNA independent of calcium and calcitriol in normal rats. Kidney Int 1996; 50: 1872–8.

Almaden Y. , Canalejo A. , Hernandez A. Direct effect of phosphorus on parathyroid hormone secretion from whole rat parathyroid gland in vitro. J Bone Miner Res 1996; 11: 970–6.

Almaden Y. , Canalejo A. , Añon G. , Rodriguez M. The role of arachidonic acid in the stimulation of PTH secretion by high phosphorus. J Am Soc Nephrol 1997; 8: 570 (A).

Brown E.M. , Wilson R.E. , Eastman R.C. , Pallotta J. , Marynick P. Abnormal regulation of parathyroid hormone release by calcium in secondary hyperparathyroidism due to chronic renal failure. J Clin Endocrinol Metab 1982; 54: 172–9.

LeBoff M.S. , Shoback D. , Brown EMX . Regulation of parathyroid hormone release and cytosolic calcium by extracellular calcium in dispersed and cultured bovine and pathological human parathyroid cells. J Clin Invest 1985; 75: 49–57.

Naveh-Many T. , Rahamimov R. , Livni N. , Silver J. Parathyroid cell proliferation in normal and chronic renal failure rats: the effect of calcium, phosphate and vitamin D. J Clin Invest 1995; 96: 1786–93.

Brown E.M. , Gambra G. , Riccardi R. Cloning and characterization of extracellular Ca^2± sensing receptor from bovine parathyroid. Nature 1993; 366: 575–80.

Pollack M.R. , Brown E.M. , Chou Y-HW . Mutations in the human Ca²-sensing receptor gene cause familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Cell 1993; 75: 1297–303.

Ramirez J.A. , Goodman W.G. , Gornbein J . Direct in vivo comparison of calcium regulated parathyroid hormone secretion in normal volunteers and patients with secondary hyperparathyroidism. J Clin Endocrinol Metab 1993; 76: 1489–94.

Goodman W.G. , Veldhuis J.D. , Gales B. , Juppner H. , Salusky I.B. : Calcium-sensing by the parathyroids in severe secondary hyperparathyroidism before parathyroidectomy. J Am Soc Nephrol 1997; 8: 574(A).

Evanson J.M. : The effect of the infusion of parathyroid extracts in hypocalcemic states. Clin Sci 1966; 31: 63–75.

Massry S.G. , Coburn J.W. , Lee D.B.N. , Jowsey J. , Kleeman C.R. Skeletal resistance to parathyroid hormone in renal failure. Studies in 195 human subjects. Ann Intern Med 1973; 78: 357–64.

Massry S.G. , Stein R. , Garty J . Skeletal resistance to the calcemic action of parathyroid hormone in uremia: role of 1,25(OH)2D3. Kidney Int 1976; 9: 467–74.

Rodriguez M. , Martin-Malo A. , Martinez M.E. , Felsenfeld A.J. , Llach F. Calcemic response to parathyroid hormone in renal failure: role of phosphorus and its effects on calcitriol. Kidney Int 1991; 40: 1055–62.

Tian J. , Smogorzewski M. , Kedes L. , Massry S.G. : PTH-PTHrP receptor mRNA is downregulated in chronic renal failure. Am J Nephrol 1994; 14: 41–6.

Ureña P. , Kubrusly M. , Mannstadt M. The renal PTH/PTHrP receptor is down-regulated in rats with chronic renal failure. Kidney Int 1994; 45: 605–11.

Andress D.L. , Howard G.A. , Birnbaum R.S. Identification of a low molecular weight inhibitor of osteoblast mitogenesis in uremic plasma. Kidney Int 1991; 39: 942–5.

Quarles D.L. , Lobaugh B. , Murphy G. Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia. J Clin Endocrinol Metab 1992; 75: 145–50.

Fukagawa M. , Kitaoka M. , Kurokawa K. Resistance of the parathyroid glands to vitamin D in renal failure: Implications for medical management, Kidney Int 1997; 62(Suppl): 60–4.

Cannella G. , Bonucci E. , Rolla D . Evidence of healing of secondary hyperparathyroidism in chronically hemodialyzed uremic patients treated with long-term intravenous calcitriol. Kidney Int 1994; 42: 1124–32.

Coen G. , Mazzaferro S. , Bonucci E. Treatment of secondary hyperparathyroidism of predialysis chronic renal failure with low doses of 1.25(OH)₂D3: humoral and histomorphometric results. Mineral Electrolyte Metab 1986; 12: 375–82.

Goodman W.G. , Coburn J.W. The use of 1.25-dihydroxyvitamin D3 in early renal failure. Annu Rev Med 1992; 43: 227–37.

Hamdy N.A. , Kanis J.A. , Beneton M.N.C. Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. BMJ 1995; 310: 358–63.

Ritz E. , Kuster S. , Schmidt-Gayk H. Low-dose calcitriol prevents the rise in 1,84 iPTH without affecting serum calcium and phosphate in patients with moderate renal failure (prospective placebo-controlled multicentre trial). Nephrol Dial Transplant 1995; 10: 2228–34.

Fournier A. , Idrissi A. , Sebert J. Preventing renal bone disease in moderate renal failure with CaCO3 and 25(OH) vitamin D3. Kidney Int 24 (Suppl): 178–9.

Okada K. , Takahashi S. , Yanai M. , Maejima M. , Nagura Y. , Hatano M. Is administration of vitamin D metabolite needed for the treatment of secondary hyperparathyroidism at the predialytic stage? Nephron 1991; 58: 492–3.

Johnson W.J. Optimum dialysate calcium concentration during maintenance hemodialysis. Nephron 1976; 17: 241–58.

Malberti F. , Scanziani R. , Corradi B. High-dose oral calcitriol and zero calcium peritoneal solutions in CAPD patients with refractory seconday hyperparathyroidism. Nephrol Dial Transplant 1994; 9: 1759–64.

Mactier R.A. , Van Stone J. , Cox A. Calcium carbonate is an effective phosphate binder when dialysate calcium concentration is adjusted to control hypercalcemia. Clin Nephrol 1987; 28: 222–6.

De Vincenzi A. , Bellazzi R.G. , Santagostino M . High and low-flux acetate free biofiltration: experimental assessment of calcium mass balance and intact parathyroid hormone behaviour. Nephrol Dial Transplant 1994; 9: 1305–9.

Argiles I. , Ciscart A. Points to remember when selecting dialysate calcium concentration. Nephrol Dial Transplant 1995; 10: 451–4.

Ritz E. , Passlick-Deetjen J. , Lippert J. What is the appropriate dialysate calcium concentration for the dialysis patients? Nephrol Dial Transplant 1996; 3(Suppl): 91–5.

Farrington K. , Mohammed M.N. , Newman S.P. , Varghese Z. , Moorhead J.F. Comparison of radioisotope methods for the measurement of phosphate absorption in normal subjects and in patients with chronic renal failure. Clin Sci 1981; 60: 55–63.

Ramirez J.A. , Emmett M. , White M.G. The absorption of dietary phosphorus and calcium in hemodialysis patients. Kidney Int 1986; 30: 753–9.

Wegmann T.B. , Kaye M. Malabsorption of calcium and phosphate in chronic renal failure: ³²P and ⁴⁵Ca studies in dialysis patients. Clin Nephrol 1990; 34: 35–41.

Cannella G. Moriero E, Rolla D. Practical guidelines for effective treatment of the osteodystrophic uraemic syndrome with intravenous calcitriol. Nephrol Dial Transplant 1996; 3(Suppl): 50–3.

Llach F. The importance of achieving optimal control of serum phosphorus. Nephrol Exchange 1996; 6: 1–11.

Burke S.K. , Slatopolsky E.A. , Goldberg D.I. RenaGel^®, a novel calcium- and aluminium-free phosphate binder, inhibits phosphate absorption in normal volunteers. Nephrol Dial Transplant 1997; 12: 1640–4.

Fischbach M. , Hamel G. , Simeoni U. , Geisert J. Phosphate dialytic removal: enhancement of phosphate cellular clearance by biofiltration (with acetate-free buffer dialysate). Nephron 1992; 62: 155–60.

Liu S.H. , Chu H.I. Studies of calcium and phosphorus metabolism with special reference to pathogenesis and effect of dihydrotachysterol (AT10) and iron. Medicine 1943; 22: 103–61.

Brumbaugh P.F. , Hughes M.R. , Haussler M.R. Cytoplasmic and nuclear binding components for 1.25-dihydroxyvitamin D3 in chick parathyroid glands. Proc Natl Acad Sci USA 1975; 72: 4871–5.

Slatopolsky E. , Weerts C. , Thielan J. , Horst R. , Harter H. , Martin J.K. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1.25-dihydroxycholecalciferol in uremic patients. J Clin Invest 1984; 74: 2136–43.

Sweny P. Optimum route of administration of vitamin D in renal failure. Nephrol Dial Transplant 1995; 4(Suppl): 29–32.

Reichel H. Optimum mode of administration of vitamin D in renal failure. Insights from experimental data. Nephrol Dial Transplant 1995; 4(Suppl): 33–6.

Indridason O.S. , Quarles L.D. Oral versus intravenous calcitriol: is the route of administration really important? Current Opinion Nephrol Hypert 1995; 4: 307–12.

Quarles L.D. , Yohay D.A. , Carrol B.A. Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD. Kidney Int 1994; 45: 1710–21.

Brown A.J. , Ritter C.R. , Finch J.L. The noncalcemic analogue of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion. J Clin Invest 1989; 84: 728–32.

Posner G.H. New vitamin D analogues. Nephrol Dial Transplant 1996; 11(Suppl): 32–36.

Finch J.L. , Brown A.J. , Slatopolsky E. Differential effects of 1.25-(OH)₂D3 and 19-nor-1.25-(OH)₂D3 on calcium and phosphate resorption in bone. J Am Soc Nephrol 1997; 8: 573(A).

Levine B.S. , Singer F.R. , Bryce G.F. , Mallon J.P. , Miller O.N. , Coburn J.W. Pharmacokinetics and biologic effects of calcitriol in normal humans. J Lab Clin Med 1985; 105: 239–46.

Salusky I.B. , Goodman W.G. , Horst R . Pharmacokinetics of calcitriol in continuous ambulatory and cycling peritoneal dialysis patients. Am J Kidney Dis 1990; 16: 126–32.

Cantley L.K. , Russel J. , Lettieri D. , Sherwood S.M. 1.25-dihydroxyvitamin D3 suppresses parathyroid hormone secretion from bovine parathyroid cells in tissue culture. Endocrinology 1985; 117: 2114–9.

Seidel A. , Herrman P. , Günther K. , Mehls O. , Schmidt-Gayk H. , Ritz E. Kinetics of plasma iPTH(1–84) after high dose of calcitriol in uremic patients. Clin Nephrol 1993; 39: 210–3.

Messa P. , Mioni G. , Bresadola F. , Montanaro D. , Risaliti A. Further characterization of persistent hyperparathyroidism in renal transplanted patients. J Am Soc Nephrol 1997; 8: 577(A).

Parfitt A.M. The hyperparathyroidism of chronic renal failure: a disorder of growth. Kidney Int 1997; 52: 3–9.